



Australian
Competition &
Consumer
Commission

Our Ref: 55039
Contact Officer: Tess Macrae, Darrell Channing
Contact Phone: (03) 9290 1835, (02) 6243 4925

GPO Box 3131
Canberra ACT 2601

23 Marcus Clarke Street
Canberra ACT 2601

tel: (02) 6243 1111
fax: (02) 6243 1199

www.accc.gov.au

3 July 2014

Dear Sir/Madam

Medicines Australia Limited application for revocation of authorisations A91316-A91320 and substitution of new authorisations A91436-A91440 – interested party consultation

The Australian Competition and Consumer Commission (the ACCC) is currently conducting a consultation process on an application for re-authorisation (application for revocation and substitution) received from Medicines Australia Limited (Medicines Australia) on 2 July 2014.

Medicines Australia has sought re-authorisation in respect of Edition 18 of the Medicines Australia Code of Conduct, which is a voluntary industry code of conduct for the prescription medicines industry in Australia.

The ACCC previously granted re-authorisation to Edition 17 of the Medicines Australia Code of Conduct until 11 January 2015.

The purpose of this letter is to invite you, as a potentially interested party, to comment on the application. Please see the ACCC's publication [Authorisation process - the basics](#) for a summary of the authorisation process and how to make a submission to the ACCC.

A copy of the application is attached and is also available on the ACCC's website www.accc.gov.au/AuthorisationsRegister.

Request for submissions

The ACCC invites you to make a submission on the likely public benefits and effect on competition, or any other public detriment, from the proposed arrangements.

Further, the ACCC invites you to outline your general experience of the arrangements during the term of the previous authorisation. The ACCC would also welcome your views on the public benefits and detriments you consider have actually resulted from the arrangements during the previous authorisation period.

If you intend to provide a submission in relation to Medicines Australia's application for re-authorisation please do so by **1 August 2014**. Please email your submission to adjudication@acc.gov.au with the subject "A91436-A91440 – Medicines Australia Limited – submission".

Submissions, including oral submissions, will be placed on the ACCC's public register subject to any request for exclusion. Please see the ACCC's publication [Guidelines for excluding information from the public register](#).

Timetable

The ACCC will progress its assessment of the application in a timely manner. An indicative timetable is set out below for your information.

Indicative date	Stage in assessment process
2 July 2014	Lodgement of application and supporting submission.
3 July 2014	Public consultation process begins.
1 August 2014	Closing date for submissions from interested parties.
August 2014	Applicant responds to issues raised in the public consultation process.
September/October 2014	Draft determination.
September/October 2014	Public consultation on draft determination including any conference if called.
November/December 2014	Final determination.

Please advise if you do not wish to make a submission at this time, but would like to be informed of the progress of the application at the draft and final determination stages. If you are able to, please provide a nominated contact email address for future correspondence.

You can also forward this letter to any other party who may wish to make a submission to the ACCC regarding the application.

This letter has been placed on the ACCC's public register. If you wish to discuss any aspect of this matter, please do not hesitate to contact Tess Macrae on (03) 9290 1835 or Darrell Channing on (02) 6243 4925, or adjudication@acc.gov.au.

Yours sincerely



Dr Richard Chadwick
General Manager
Adjudication Branch

Medicines Australia Limited - Revocation and Substitution - A91436 - A91440

A number of individual healthcare professionals and other interested individuals

Abbott Laboratories

AbbVie Pty Ltd

ACT Health

ACT Minister for Health

Allergan Australia Pty Ltd

Alphapharm

Amgen Australia Pty Ltd

Astrazeneca

Atlantis Healthcare

Australasian College of Dermatologists

Australasian Medical Writers Association

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists

Australia and New Zealand Bone and Mineral Society

Australian General Practice Network

Australian Institute of Medical Scientists

Australian Medical Association

Australian Nursing Federation

Australian Primary Health Care Nurses Association (APNA)

Australian Self Medication Industry

Australian Skeptics

Australian Society of Anaesthetists

Baxter Healthcare

Bayer Schering

Boehringer Ingelheim Pty Ltd

Bristol-Myers Squibb
Cancer Voices Australia
Cardiac Society of Australia and New Zealand
Celgene Pty Ltd
Central Hospital Supplies
CHOICE
Communications Council
Consumers Federation of Australia
Consumers Health Forum of Australia
Council of Australian Therapeutic Advisory Groups
CSL Limited
Datapharm Australia
Department of Health and Ageing
Department of Health and Ageing, Therapeutic Goods Administration
Department of Health, ACT
Department of Health, NSW
Department of Health, QLD
Department of Health, QLD - Medicines Regulation and Quality
Department of Health, South Australia
Department of Health, Tasmania
Department of Health, Victoria
Department of Health, Western Australia
Doctors' Reform Society of Australia
Electronic Distribution Working Group
Eli Lilly
Ferring Pharmaceuticals
FIT BioCeuticals Ltd

Friends of Science and Medicines
Generic Medicines Industry Association
GlaxoSmithKline
Health Issues Centre
Healthy Skepticism Inc
Ipsen Pty Ltd
Janssen Pty Ltd
Lundbeck Australia Pty Ltd
Medical Oncology Group of Australia Incorporated (MOGA)
Medical Technology Association of Australia
Mental Health Council of Australia
Mental Illness Fellowship of Australia
Merck Serono Australia Pty Ltd
Merck Sharp & Dohme (Australia) Pty Ltd
mmw3degrees
National Health and Medical Research Council
National Medicines Policy Committee
National Prescribing Service
Novartis
NSW Minister for Health
NSW Therapeutic Advisory Group
Pfizer Australia Pty Ltd
Pharma in Focus
Pharmaceutical Benefits Scheme
Pharmaceutical Society of Australia
Pharmacy Guild of Australia
PriceWaterhouseCoopers

ProScribe
Quintiles Pty Ltd
Roche Products Pty Limited
Royal Australasian College of Physicians
Royal Australasian College of Surgeons
Royal Australian and New Zealand College of Ophthalmologists (RANZCO)
Royal Australian and New Zealand College of Psychiatrists
Royal Australian College of General Practitioners
Royal Australian College of Medical Administrators
Royal Children's Hospital (Melbourne) - Medical Staff Association
Royal College of Pathologists of Australasia
Sanofi
Servier Laboratories (Aust) Pty Ltd
Shire Australia
Sigma Pharmaceuticals
Society of Hospital Pharmacists of Australia (SHPA)
South Australian Medicines Advisory Committee (SAMAC)
South East Sydney Local Health District Drug and QUM Committee
Summerdale Medical Centre
Takeda Pharmaceuticals Australia Pty Ltd
University of SA - School of Pharmacy and Medical Sciences
University of Wollongong - Centre for Health Initiatives
Westmead Hospital - Department of Diabetes and Endocrinology